Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1989): Kerker BJ+, Semin Dermatol 8, 173
(1987): Katsanis E+, Am J Pediatr Hematol Oncol 9, 204
(1984): Flynn TC+, JAmAcadDermatol11, 584
Petechiae
(1998): Taverna C+, Schweiz Med Wochenschr (German)
128, 1117
Photo-recall
(2006): Kaya TI+, J Eur Acad Dermatol Venereol 20(3), 353
Pruritus (1–10%)
Rash (sic) (>10%)
(2002): Cetkovska P+, J Eur Acad Dermatol Venereol 16(5), 481
(40–73%)
Seborrheic keratoses (inflammation of)
(Leser–Trélat syndrome)
(1999): Williams JV+, JAmAcadDermatol40, 643
Squamous syringometaplasia
(1990): Bhawan J+, Am J Dermatopathol 12, 1
Toxic epidermal necrolysis
(2001): Özkan A+, Pediatr Dermatol 18(1), 38
(1998): Figueiredo MS+, Rev Assoc Med Bras (Portuguese) 44, 53
Ulcerations
Urticaria
(2002): Cetkovska P+, J Eur Acad Dermatol Venereol 16(5), 481
Vasculitis*
(1998): Ahmed I+, Mayo Clin Proc 73, 239
(1989): Kerker BJ+, Semin Dermatol 8, 173
(1989): Williams SF+, Br J Haematol 73, 274
Mucosal
Oral lesions
(1986): Morant R+, Schweiz Med Wochenschr (German)
116, 1415 (1–5%)
Oral ulceration (>10%)
Perianal ulcerations (>10%)
Stomatitis
(1988): Benson PM+, J Assoc Military Derm XIV, 28 (passim)
Hair
Hair – alopecia (1–10%)
(1988): Benson PM+, J Assoc Military Derm XIV, 28 (passim)
(1986): Morant R+, Schweiz Med Wochenschr (German)
116, 1415 (100%)
Nails
Nails – leukonychia
(1990): Bader-Meunier B+, Ann Pediatr Paris (French) 37, 337
Nails – Mees’ lines
(1982): Jeanmougin M+, Ann Dermatol Venereol (French)
109, 169
Eyes
Conjunctivitis
(2006): Matteucci P+, Haematologica 91(2), 255
Other
Anaphylactoid reactions/Anaphylaxis
(1997): Blanca M+, Allergy 52, 1009
(1989): Williams SF+, Br J Haematol 73, 274
(1980): Rassiga AL+, Arch Intern Med 104, 425
Hypersensitivity
(1992): Weiss RB, Semin Oncol 19, 458
Infections
(1997): Whitlock JA+, Leukemia 11(2), 185 (39%) (with
etopside)
Injection-site cellulitis (1–10%)
Myalgia/Myositis/Myopathy/Myotoxicity (1–10%)
Neurotoxicity
(2006): Nakajima D+, No To Hattatsu 38(3), 195
(2006): Saito T+, J Infect Chemother 12(3), 148
Rhabdomyolysis
(2002): Truica CI+, Am J Hematol 70(4), 320
(1997): Morales-Polanco M+, Arch Med Res 28(3), 377 (5 cases)
(1987): Margolis D+, Cancer Treat Rep 71(12), 1325
Thrombophlebitis (>10%)
*Note: Vasculitis, a part of the cytarabine syndrome, consists of
fever, malaise, myalgia, conjunctivitis, arthralgia and a diffuse
erythematous maculopapular eruption that occurs from 6 to 12 hours
following the administration of the drug
DACARBAZINE
Synonym: DIC
Trade names: D.T.I.C; Dacatic; Deticene; Detimedac; DTIC-
Dome (Bayer)
Indications: Malignant melanoma, carcinomas
Category: Alkylating agent; Antineoplastic
Half-life: initial: 20–40 minutes
Clinically important, potentially hazardous interactions
with: aldesleukin
Reactions
DACARBAZINE 159
Skin
Actinic keratoses
(1987): Johnson TM+, JAmAcadDermatol17(2 Pt 1), 192
Angioedema
(1981): Wassilew SW+, Hautarzt (German) 32 (Suppl 5), 453
Erythema
Exanthems
(1981): Wassilew SW+, Hautarzt (German) 32 (Suppl 5), 453
Fixed eruption
(1982): Koehn GG+, Arch Dermatol 118, 1018
Photosensitivity (